- Home
- SBR vs SEPN Comparison
SBR vs SEPN Comparison
Compare SBR & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBR
- SEPN
- Stock Information
- Founded
- SBR 1982
- SEPN 2022
- Country
- SBR United States
- SEPN United States
- Employees
- SBR N/A
- SEPN N/A
- Industry
- SBR Oil & Gas Production
- SEPN
- Sector
- SBR Energy
- SEPN
- Exchange
- SBR Nasdaq
- SEPN NYSE
- Market Cap
- SBR 972.2M
- SEPN 453.2M
- IPO Year
- SBR N/A
- SEPN 2024
- Fundamental
- Price
- SBR $66.44
- SEPN $11.76
- Analyst Decision
- SBR
- SEPN Strong Buy
- Analyst Count
- SBR 0
- SEPN 5
- Target Price
- SBR N/A
- SEPN $26.75
- AVG Volume (30 Days)
- SBR 28.9K
- SEPN 443.6K
- Earning Date
- SBR 01-01-0001
- SEPN 08-15-2025
- Dividend Yield
- SBR 8.22%
- SEPN N/A
- EPS Growth
- SBR N/A
- SEPN N/A
- EPS
- SBR 5.34
- SEPN N/A
- Revenue
- SBR $81,761,891.00
- SEPN $977,000.00
- Revenue This Year
- SBR N/A
- SEPN N/A
- Revenue Next Year
- SBR N/A
- SEPN $526.96
- P/E Ratio
- SBR $12.37
- SEPN N/A
- Revenue Growth
- SBR N/A
- SEPN 108.76
- 52 Week Low
- SBR $58.25
- SEPN $4.17
- 52 Week High
- SBR $70.20
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- SBR 50.84
- SEPN N/A
- Support Level
- SBR $66.05
- SEPN N/A
- Resistance Level
- SBR $67.20
- SEPN N/A
- Average True Range (ATR)
- SBR 1.14
- SEPN 0.00
- MACD
- SBR -0.03
- SEPN 0.00
- Stochastic Oscillator
- SBR 66.17
- SEPN 0.00
About SBR Sabine Royalty Trust
Sabine Royalty Trust is an express trust which is formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.